A trial for potential Ebola treatments has commenced in the Democratic Republic of Congo as of Friday, according to the World Health Organization (WHO). The trial is crucial as the country faces a deadly outbreak, with over 1,400 confirmed cases and 438 deaths reported.
Current Ebola Outbreak Details
The ongoing Ebola outbreak in DR Congo, which began in May, has escalated into a public health emergency. The WHO has confirmed 1,460 cases as of July 1, with an additional 150 suspected cases and 452 deaths. The outbreak primarily affects three eastern provinces: South Kivu, North Kivu, and Ituri. However, there are concerns about the situation spreading to surrounding areas.
On July 1, it was reported that a pregnant woman’s body tested positive for Ebola in Tshopo province, raising alarms as she had died in Ituri before her body was transported. Additionally, a suspected Ebola patient fled from an isolation unit in Ituri and later tested positive in Haut-Uele province. Health authorities are actively conducting contact tracing in these regions.
Trial Overview and Potential Treatments
The trial, which is being coordinated by scientists from the Institut National de Recherche Biomédicale in DR Congo, the Institute of Tropical Medicine in Belgium, and the University of Oxford in the UK, aims to test two antiviral drugs on enrolled patients. WHO chief Tedros Adhanom Ghebreyesus emphasized the importance of developing safe and effective therapeutics, stating, "Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit."
